Connect with us

Featured

Should I Buy A House Or Invest In The Stock Market?

Joe Samuel

Published

on

stock price

Home ownership is one of the biggest financial commitments most will make in his or her life while investing in stocks is generally seen as a key component of building wealth.

Using house-price indexes from the Federal Housing Finance Agency (FHFA) and prices for the S&P 500 from Yahoo Finance going back to 1991, take a look at how the two compared at various times in the past 27 years, as well as how housing prices in some of the biggest cities in the US have fared against stocks.

In most cases, stocks have outshined housing prices over the decades, as a nine-year bull market continues to roar.

It’s worth seeing that this is a very basic comparison. Stocks and houses are, of course, two very different types of investments. Home ownership comes with property taxes and upkeep costs, but also offers the key service of being a place for someone to live that stocks clearly do not. Stock ownership can involve brokerage and other fees.

Further, stock prices tend to be more volatile over time than housing prices. While it is possible to accrue great riches in the stock market, it’s also quite possible to lose it all. Housing prices have tended to increase more gradually over time, but as the mid-2000s housing bubble and underlying bust showed, that increase is far from guaranteed.

Given those facts, here’s how two of the most important financial markets for ordinary Americans have evolved over the past three decades:

A. Even with the dot-com crash and the stock-market crash in the wake of the financial crisis of the late 2000s, the cumulative gains in the stock market since the beginning of the 1990s have resulted in a gain of over 700%, while housing prices have increased 164% in that time.

B. Housing prices are up about 85% while stocks are up 79% since September 2000, when the stock market peaked during the tech bubble.

C. Housing prices are up 60% and stocks are up 233% since October 2002.

D. Stocks are up 93% since the FHFA house-price index topped out in March 2007, while housing took a long time to recover. Housing prices are up just 17% in the past 11 years, with the FHFA index not fully recovering until 2016.

E. Housing prices are up 21% since November 2007, while stocks are up 76%.

F. Stocks are up 273% since hitting a low in March 2009, while housing prices are up 36%.

G. Housing prices are up 48% from May 2011, when the FHFA index hit its post-crisis low, while stocks are up 99%.

H. Stocks are up nearly 700% since January 1991, while housing prices in the New York-Jersey City-White Plains metropolitan division are up 174%.

I. As of the second quarter of 2018, housing prices in the Miami-Miami Beach-Kendall metropolitan division are up 297% since Q1 1991.

J. Housing prices in the Denver-Aurora-Lakewood metropolitan area are up 413% since Q1 1991, still below the nearly 700% increase in stock prices.

After looking at the numbers we see that this is only one thing to consider, and it’s vital to keep in mind that past performance can’t determine the future.

This doesn’t mean that stocks are the end all investment for everyone at every time, or that buying a home is bad. Everyone has different financial and housing goals, with several aspects involved in making these kinds of decisions.

Continue Reading
Click to comment

Featured

Biotechnology Could Cure It All

Daniel Chase

Published

on

stock_price_biotech

Nearly two-thousand years ago, give or take several minutes, Hippocrates taught that human existence was centered around the four elements — earth, water, fire, and air — which in the human body was represented by the four basic humors: blood, phlegm, black bile, yellow bile. Hippocrates explained that each humor was located in a specific organ of the human body and each related to its own personality type — sanguine, phlegmatic, melancholic, and choleric.

‘Therefore, if someone was sick, Hippocrates taught that this indicated an imbalance in one of the four humors, so treatment included removing a given amount of the imbalanced humor through purging, bloodletting, etc. For those unfamiliar with bloodletting, it is the removal of some a patient’s blood which, in modern times, seems completely feasible, but back then this involved draining blood out of a person. 

Suffice to say that the medical field has moved forward since 460 BC, and recently, these advancements have occurred in the biotechnology industry. Though biotech is a relatively new field, it possesses great potential for the future of medicine. One of the more recent breakthroughs in biotech stems from something called pharmacogenomics, or the study of how genetics affect a person’s response to drugs. This new field combines the science of developing drug treatments and research conducted on human genetics and their functions. 

Multi-Trillion Dollar Industry Providing Massive Opportunity in 2019 & Beyond

According to the U.S. National Library of Medicine, most drugs currently available on the market are branded as “one size fits all,”meaning that this specific treatment was created to cure a certain ailment for anyone who takes it. However, as scientists in the pharmacogenomics field are discovering, not everyone reacts the same to certain drugs.

For example, if two individuals are having an allergic reaction and both ingest an anti-histamine, it’s possible that it will help one person feel better, while causing adverse side-effects to the other person. By studying a person’s genetic coding, medical experts are better able to predict how a medication will effect a particular person. 

Ironically enough, as new technologies and inventive approaches to curing diseases come to light, medical researchers are discovering new diseases that seek to test all the progress we’ve made thus far. The practices of medicine have taken massive strides over the past few generations through the pioneering of biotechnology research and other incredible advancements, but regardless of these steps forward, it is up to companies in the healthcare industry to responsibly tend to the needs of their patients. 

Premier Health Group Inc. (OTC: PHGRF) / (CSE: PHGI) / (6PH.F) is a Canadian publicly traded company strategically poised to take advantage of lucrative business opportunities in the global healthcare industry. The Company is working to develop innovative healthcare approaches that combine human skill-based expertise with emerging technologies. What sets the Company apart from others in the field is that Premier is focused on developing their healthcare platform with a patient centric focus, looking to restore power back to the patients. For far too long, patients have been at the mercy of pharmaceutical companies who, by virtue of their capital, have maintained a chokehold on the price of drugs that patients need to stay healthy. 

In addition to rising treatments costs, as the global population increases, there are less primary physicians available for consumers looking to be cured. Through the use of Premier Health Group Inc. (OTC: PHGRF) / (CSE: PHGI) / (6PH.F) HealthVue app, patient can see their physician, access their charts & lab results, chat securely with clinical staff, reorder prescriptions and share remote health monitoring data with their doctor – all at their fingertips. The HealthVue app utilizes a virtual care platform designed to be easy to use and to improve a patient’s access to primary care. 

In addition these advanced healthcare solutions, the Company shared, in their most recent corporate update, that they plan on utilizing artificial intelligence to assist in virtually triaging the needs of their patients. Using their Healthvue app, the patient will answer a series of questions which will be relayed to the physician, along with a differential on possible diagnoses. This information will be pre-populated to the physicians charting system and will provide key patient information prior to the scheduled virtual visit, saving them a considerable amount of time and allowing more time for patient interaction. 

Pursuant to an agreement between MIDAM VENTURES, LLC and Premier Health Group Inc. we were hired for a period from 10/1/2018 – 4/1/2019 to publicly disseminate information about Premier Health Group Inc. including on the Website and other media including Facebook and Twitter. We were paid $300,000 ( CASH) for & were paid “500,000” shares of restricted common shares (as of 1/2/2019). We own zero shares of Premier Health Group Inc., which we purchased in the open market. Once the (6) Six-month restriction is complete on 4/1/2019 we plan to sell the “500,000” shares of Premier Health Group Inc. that we hold currently in restricted form during the time the Website and/or Facebook and Twitter Information recommends that investors or visitors to the website purchase without further notice to you. We may buy or sell additional shares of Premier Health Group Inc. in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. Please click here for full disclaimer.

Continue Reading

Featured

Stock Price Newsletter – February 21, 2019

Joe Samuel

Published

on

stock price newsletter

One Stock To Watch Ahead Of Healthcare Boom

See For Yourself


The Future Is Delicious

Details Here


Here’s What You Missed 2/20/19

Get The Full Story Here


Continue Reading

Featured

Mueller Investigation Is Almost Ready

Daniel Chase

Published

on

stock_price_mueller

A half-witted, know-nothing playwright by the name of William Shakespeare once wrote that “these violent delights have violent ends.” The line, taken from Shakespeare’s Romeo and Juliet, also featured in Westworld, depicts a scene in which Friar Laurence cautions Romeo into falling for Juliet because his love may catalyze his own violent end. I attribute the words of Shakespeare to the current predicament facing President Donald Trump and his administration. In the two or so years since Trump took office, special counsel Robert Mueller has worked without end to investigate whether the Trump administration colluded in any way, shape, or form, with Russia during the 2016 presidential election. 

After countless subpoenas and inducements of former Trump associates and administration members, sources indicate that Mueller’s long nights away from the family could soon be over. Towards that end of January, Roger Stone, a former associate of Donald Trump before he became president, was indicted on charges of seeking stolen emails from WikiLeaks that could damage Trump’s opponents during the 2016 presidential election season. 

Per the official language of the indictment:

“…After the 2016 U.S. presidential election, the U.S. House of Representatives Permanent Select Committee on Intelligence, the U.S. Senate Select Committee on Intelligence, and the Federal Bureau of Investigation opened or announced their respective investigations into Russian interference in the 20126 U.S. presidential election…Stone took steps to obstruct these investigations….He made false statements to the HPSCI about his interactions regarding WikiLeaks, and falsely denied possessing records that contained evidence…”

-Robert Stone indictment 

The indictment went on to explain that Stone attempted to persuade a witness to provide false testimony and withheld pertinent information from federal investigators. According to several sources, Stone was arrested by the FBI Friday morning while drinking his morning coffee at his home in Florida. Stone’s attorney immediately attempted to defuse any public sentiment stirring up connecting Stone to special counsel Mueller’s investigation, suggesting that Stone’s indictment “focuses on allegedly false statements…made to Congress,” and has nothing to do with Russian collusion. 

According to CNN, Attorney General Bill Barr is limbering up in preparation to announce as early as next week the completion of Robert Mueller’s investigation, “with plans for Barr to submit to Congress soon after a summary” of the confidential report is prepared. Interestingly enough, though the details of the report concern both the American people and its presiding government, under special counsel regulations, Mueller must submit his “report” to the attorney general and the law doesn’t require this document to be shared with anyone.

Barr is under no formal obligation to publicly share the report, but I can already assume that members of the Democratic leadership will be banging on his office door until he throws them a bone. 

The question on everyone’s mind is, what Mueller discovered in his lengthy investigation. Mueller was appointed to the case on May 17, 2017, and in years following this date, Mueller has had his hands full. Early last week, Mueller’s office filed its sentencing memorandum against Paul Manafort, Trump’s former campaign manager, who will be sentenced next month in federal district court in the District of Columbia. 

“For a decade, Manafort repeatedly violated the law. Considering only the crimes charged in this district, they make plain that Manafort chose to engage in a sophisticated scheme to hide millions of dollars from United States authorities. The sentence in this case must take into account the gravity of this conduct, and serve to both specifically deter Manafort and those who would commit a similar series of crimes.”

sentencing memo from Robert Mueller

As for the findings of Mueller’s investigation, we will have to wait and see how Attorney General Barr chooses to go about sharing the report, if he ends up sharing the information at all. The information could disturb the Trump presidency and possibly give Democrats grounds for introducing articles of impeachment. 

Continue Reading

Join Our Newsletter

Get stock alerts, news & trending stock alerts straight to your inbox!


We keep all user information pricate & promise to never spam.*

Privacy Policy

Search Stock Price (StockPrice.com)




Trending

Subscribe Now & Begin Receiving Free Stocks News, Articles, Trade Alerts & MORE, all 100% FREE!

We are your #1 source for all things Stock Market & Finance, Subscribe Below!

Privacy Policy: We will NEVER share, sell, barter, etc. any of our subscribers information for any reason ever! By subscribing you agree we can send you via email our free e-newsletter on stock market & finance related, articles, news and trade alerts. Further questions please contact privacy@stockprice.com